Trial Profile
A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability and Pharmacokinetics of PMN310 Infusions in Healthy Volunteers
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs PMN 310 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; First in man
- Sponsors ProMIS Neurosciences
- 08 Jan 2024 According to a ProMIS Neurosciences media release, the company is expecting to report data on this study around mid-2024.
- 08 Jan 2024 According to a ProMIS Neurosciences media release, the company received clearance from the Independent Data and Safety Monitoring Board to advance PMN310 to the second dose level in this Single Ascending Dose (SAD) trial in healthy volunteers.
- 20 Nov 2023 Status changed from not yet recruiting to recruiting, according to the ProMIS Neurosciences media release.